Skip to main content
JNJ logo

Johnson & Johnson (JNJ) Stock Price & Analysis

Johnson & Johnson (JNJ) — MoonshotScore 84/100 (Exceptional band), calculated Nov 22, 2026. Price $270.47 (+1.25%), as of the Nov 20, 2026 trading session; market cap $651B. Expected results Jan 20, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 37.79× (market value Nov 20, 2026; cash Sep 27, 2026) · expected results Jan 20, 2027

$270.47 +$3.33 (+1.25%) Market Cap $651B

Johnson & Johnson · JNJ · NYSE · Healthcare · Drug Manufacturers - General

Research dated 2026-09-13: Johnson & Johnson combines prescription medicines with devices used in surgery, orthopaedics, vision care and interventional treatment. Its scale matters less than whether rising sales can keep translating into durable operating profit and cash generation across Innovative Medicine and MedTech.

Price as of Nov 20, 2026

Key Statistics

84 of 100

MoonshotScore v2 · Johnson & Johnson (JNJ)

Exceptional
Business Quality Elite (90)
Financial Safety Sound (64)
Valuation Full (41)
Growth Durability Growing (74)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Jan 20, 2027
  • Altman Z 5.39 · Piotroski F 6

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for JNJ (58 recorded, newest six shown)
RecordedScoreBand
87Exceptional
84Exceptional
84Exceptional
83Exceptional
83Exceptional
83Exceptional

The score moved from 83 in the stored Nov 21, 2026 snapshot to 84 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Business Quality +1 and Valuation -1. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$270.476.8% below its 5-year high of $290.25 ()
Change on the day+1.25%
52-week range$199.91–$290.25
Market capitalisation$651B
Price / earnings (trailing)41.01
Shares traded on the day11.92M
Beta (volatility vs the S&P 500)0.24
Dividends per share (last 12 months)$5.28
Dividend yield (last 12 months)1.95%

Why Johnson & Johnson scores 84

Dr. Mira Sol, the Stock Expert AI TV data character
Drugs and medical devices together give this healthcare giant a high quality reading. Litigation and a full price keep the valuation pillar middling.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
84Exceptional
  • Business Quality90
  • Financial Safety64
  • Valuation41
  • Growth Durability74
  • Momentum89

Share price, last 12 months +31.0%

$193.72 $253.79

What the price assumes

14.6% a year of free-cash-flow growth for ten years is what a $651.00B market value () asks for.

  • Price implies, next ten years14.6%
  • Free cash flow, last 5 years-0.5%
  • Revenue, last 5 years2.7%
  • Analysts' revenue path, 2026–20307.5%

The price asks for faster cash-flow growth than recent years. That depends on the drug pipeline and the medtech business.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $18.71B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 9 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 1.7% either way.

  1. -2.2%Jan ’24
  2. -1.9%Apr ’24
  3. +2.9%Jul ’24
  4. +1.7%Oct ’24
  5. -1.0%Jan ’25
  6. -0.3%Apr ’25
  7. +5.0%Jul ’25
  8. +0.1%Oct ’25
  9. +0.1%Jan ’26
  10. +0.3%Apr ’26
  11. -1.5%Jul ’26
  12. -3.7%Oct ’26
Next-session move EPS beat (9) EPS in line (3)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatIn line-3.7%—
BeatIn line-1.5%+0.7%
In lineBeat+0.3%-5.0%
In lineBeat+0.1%+4.4%
BeatBeat+0.1%+0.5%
BeatBeat+5.0%+9.0%
BeatBeat-0.3%+0.6%
BeatIn line-1.0%+2.0%
BeatBeat+1.7%+1.1%
BeatIn line+2.9%+3.5%
BeatIn line-1.9%+1.3%
In lineBeat-2.2%-2.3%

Results beat routinely, and the shares barely react. Litigation and pipeline news move the stock more.

Our track record on this stock

Since the score went from 89 to 83 while the share price moved -0.9% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 53% of 40 rate it a buy; the average target ($285.31, captured ) sits +5.5% from the price of $270.47.
  • Last 90 days: 13 rating actions, every one a reaffirmation.
  • Our signals: Exceptional band; strongest pillar Business Quality (90), weakest Valuation (41).

Analysts are split on the healthcare giant, mostly over litigation. Our model scores the cash generation, which has stayed steady.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 24, 2025 to Nov 20, 2026: low $187, high $286, latest $270. 4 reported quarters marked, 3 above and 0 below the recorded estimate. 1 other dated event marked. $286 $187 high $286 Jan 21, 2026 · Earnings results · reported in line with the recorded estimate · close $2201Apr 14, 2026 · Earnings results · reported above the recorded estimate · close $2342Jul 15, 2026 · Earnings results · reported above the recorded estimate · close $2533Oct 13, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $2564Oct 13, 2026 · Earnings results · reported above the recorded estimate · close $2565 Oct 24, 2025 Nov 20, 2026 · $270 $190Oct 24, 2025$187Nov 7, 2025$204Nov 21, 2025$202Dec 5, 2025$206Dec 19, 2025$207Jan 2, 2026$219Jan 16, 2026$227Jan 30, 2026$243Feb 13, 2026$248Feb 27, 2026$242Mar 13, 2026$240Mar 27, 2026$238Apr 10, 2026$228Apr 24, 2026$221May 8, 2026$234May 22, 2026$233Jun 5, 2026$228Jun 18, 2026$263Jul 2, 2026$253Jul 17, 2026$256Jul 31, 2026$260Aug 14, 2026$268Aug 28, 2026$266Sep 11, 2026$271Sep 25, 2026$261Oct 9, 2026$264Oct 23, 2026$276Nov 6, 2026$270Nov 20, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · in line with the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleNov 24, 2026, Ex-dividend date; Dec 8, 2026, Dividend payment date; Jan 20, 2027, Next results due. Spacing is order only and carries no duration.Nov 20, 20261Nov 24, 20262Dec 8, 20263Jan 20, 2027
  1. Ex-dividend dateCompany record
  2. Dividend payment dateCompany record
  3. Next results dueProvider estimate

Management outlook

  • As a result, we are raising our guidance for 2026 versus our most recent update in July.

    Joseph J. Wolk · Statement from

  • We are also tightening the range of our effective tax rate guidance Based on our year to date results, we now expect a full year effective tax rate of 17.0% to 17.5%. Given those updates, we now expect adjusted operational earnings per share in the range of $10.95 to $11.05, or 2% at the midpoint.

    Joseph J. Wolk · Statement from

How to read these dates

Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Johnson & Johnson (JNJ): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Neutral
Debt/Equity Neutral
ROE Strong
Gross Margin Strong

Read on: Nov 22, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Johnson & Johnson (JNJ), and what does it report?

Short answer · as of

Johnson & Johnson is a healthcare holding company, not merely a diversified drugmaker. Innovative Medicine sells therapies spanning oncology, immunology, neuroscience and other disease areas, while MedTech supplies products tied to procedures and clinical care.

Innovative Medicine contributes more revenue, but consolidated sales and profit blend pharmaceutical demand with activity in surgery, orthopaedics, vision and interventional treatment. That reporting shape means a movement in the company total may originate from very different product and customer dynamics.

2 · Latest results

What do the latest results show for Johnson & Johnson (JNJ)?

The latest quarter showed sequential gains in revenue, gross profit, operating profit, net income and diluted earnings. Revenue and the earnings measure compared with consensus also exceeded expectations, extending a record of meeting or surpassing the displayed estimates.

Cash generation improved from the preceding quarter, although it remained below stronger periods in the recent series. Separately, management said the planned Firefly Bio acquisition would add an antibody platform and reinforce the oncology portfolio; that is a strategic claim, not an explanation for the reported improvement.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$25.40B Sep 27, 2026
Latest quarter · R&D
$4.65B Sep 27, 2026
Latest quarter · SG&A
$6.29B Sep 27, 2026
Latest quarter · FMP standardized operating result
$5.84B Sep 27, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 27, 2026$25.40B$4.65B$6.29B$5.84B
Jun 28, 2026$25.31B$3.65B$6.43B$7.17B
Mar 29, 2026$24.06B$3.53B$6.03B$6.39B
Dec 28, 2025$24.56B$4.25B$6.75B$5.59B
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$25.40B Oct 13, 2026
Latest report · revenue estimate
$25.38B Oct 13, 2026
Latest report · revenue vs estimate
Above estimate Oct 13, 2026
Latest report · EPS vs estimate
Above estimate Oct 13, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 13, 2026$25.40B$25.38B$2.5900$2.5200
Jul 15, 2026$25.31B$25.06B$2.9000$2.8500
Apr 14, 2026$24.06B$23.61B$2.7000$2.6800
Jan 21, 2026$24.56B$24.15B$2.4600$2.4600
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$23.99B$5.15B$2.12 (diluted)
Q4 FY2025$24.56B$5.12B$2.10 (diluted)
Q1 FY2026$24.06B$5.24B$2.14 (diluted)
Q2 FY2026$25.31B$5.53B$2.27 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Johnson & Johnson (JNJ)?

Short answer · as of

Cash and short-term investments were $17.23B at the Sep 27, 2026 balance-sheet date. Operating cash flow was $7.72B for the quarter ended Sep 27, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Johnson & Johnson remains profitable at substantial gross and operating margins, and every displayed quarter generated positive operating cash flow after funding ongoing research activity. Recent cash generation also exceeded capital spending, while the financial quality and distress screens remain favorable.

Liquidity deserves a more qualified reading. Cash and short-term investments sit below total debt, quick assets do not cover current obligations, and the cash balance has retreated from its recent peak. Dividend payments continued at a higher per-share rate than earlier listed payments, leaving cash conversion, leverage and distributions linked through capital allocation.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 41.01 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$7.72B Sep 27, 2026
Previous quarter · operating cash flow
$8.62B Jun 28, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 27, 2026$7.72B−$1.36B
Jun 28, 2026$8.62B−$1.32B
Mar 29, 2026$2.51B−$1.05B
Dec 28, 2025$7.31B−$1.84B
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Johnson & Johnson (JNJ)?

Short answer · as of

The next earnings report is expected on Jan 20, 2027.

The next earnings release should be read against the latest high revenue base and the established pattern of consensus outperformance. The useful checks are whether operating profit advances with sales, whether operating cash flow continues recovering, and whether cash stabilizes relative to debt.

Firefly Bio adds another checkpoint: completion would move the antibody platform from announced intent into the portfolio. Longer-range forecasts anticipate continuing revenue and earnings expansion, but analyst participation becomes progressively thinner, so execution across the operating segments matters more than the distant consensus path.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. As a reminder for your 2027 modeling, we expect Firefly Bio and Cell BioMedicines to have a combined dilutive impact of $1.36 per share on a full year adjusted earnings per share next year.

    Joseph J. Wolk ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does Johnson & Johnson compare with its peers?

Short answer

Johnson & Johnson's score ranks tied for 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a pure pharmaceutical company, Johnson & Johnson carries direct exposure to procedure volumes through surgery, orthopaedics, vision and interventional products. Compared with a pure medical-device company, its larger revenue engine is Innovative Medicine. Consolidated results therefore combine therapeutic product cycles with procedure-linked demand, and weakness in one business need not describe the other.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Same industry, near in market value$1347.11 Nov 20, 2026$1.27T98 5-pillar Nov 22, 2026
Novo Nordisk A/S (NVO) Named competitor$37.82 Nov 20, 2026$167B87 5-pillar Nov 22, 2026
Sanofi (SNY) Same industry, near in market value$46.52 Nov 20, 2026$112B87 5-pillar Nov 22, 2026
AstraZeneca PLC (AZN) Same industry, near in market value$174.35 Nov 20, 2026$270B85 5-pillar Nov 22, 2026
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$58.80 Nov 20, 2026$120B85 5-pillar Nov 22, 2026
Johnson & Johnson (JNJ) — this page$270.47$651B84
AbbVie Inc. (ABBV) Named competitor$286.20 Nov 20, 2026$506B84 5-pillar Nov 22, 2026
Amgen Inc. (AMGN) Same industry, near in market value$435.64 Nov 20, 2026$236B84 5-pillar Nov 22, 2026
Novartis AG (NVS) Named competitor$150.47 Nov 20, 2026$284B83 5-pillar Nov 22, 2026
GSK plc (GSK) Same industry, near in market value$47.76 Nov 20, 2026$95.7B77 5-pillar Nov 22, 2026
UnitedHealth Group Incorporated (UNH) Named competitor$339.85 Nov 20, 2026$305B76 5-pillar Nov 22, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$166.43 Nov 20, 2026$206B73 5-pillar Nov 22, 2026
Merck & Co., Inc. (MRK) Named competitor$133.72 Nov 20, 2026$330B68 5-pillar Nov 22, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$260.00 – $320.00
Last captured analyst target (expired, captured Nov 18, 2026)
$285.31
Last captured median analyst target (expired, captured Nov 18, 2026)
$281.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
35
Identified insiders
9
Purchases
0
Sales
11
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
73.1% Period end Sep 30, 2026
Previous quarter · ownership
74.5% Prior to period end Sep 30, 2026
Reporting holders
4,863 Period end Sep 30, 2026
Previous quarter · holders
4,831 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.209,718,001
Vanguard Capital Management LLC157,757,243
State Street Corp133,971,339
Vanguard Portfolio Management LLC65,651,392
Geode Capital Management, LLC65,497,363

Tracked investors

Which of the 16 named investors we follow held JNJ in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.63%$144.95MTrimmed −18.2% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

JNJ Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Johnson & Johnson more than a drugmaker?

Innovative Medicine is the larger segment, but MedTech also sells products used in surgery, orthopaedics, vision care and interventional treatment. The company therefore participates in medicine demand and procedure-linked healthcare spending.

Which Johnson & Johnson business contributes more revenue?

Innovative Medicine contributes more revenue than MedTech. Its portfolio spans oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolic care, and pulmonary hypertension.

How does MedTech change Johnson & Johnson’s business mix?

MedTech adds products whose use is tied to clinical procedures and surgical activity, creating demand drivers distinct from prescription medicines. That makes the consolidated revenue line a blend of therapy uptake and healthcare procedure activity.

What would Firefly Bio add to Johnson & Johnson?

Management says the planned acquisition would add another antibody platform and strengthen next-generation oncology work. The immediate point to watch is whether the transaction closes and moves from planned expansion into the operating portfolio.

What is the JNJ stock price today?

The last price recorded for Johnson & Johnson (JNJ), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the JNJ price target?

The last analyst consensus price target we captured for Johnson & Johnson (JNJ), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.

Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 2 with no recorded source, 5 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is Johnson & Johnson (JNJ), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Johnson & Johnson (JNJ)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Most recent periodic reports; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Johnson & Johnson (JNJ)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Trailing twelve-month ratio set; Distress and quality screens; Recent dividends paid
  • 4. What should you watch next at Johnson & Johnson (JNJ)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Management outlook — dated call excerpts; Analyst revenue and earnings estimates (average)
  • 5. How does Johnson & Johnson compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Why is Johnson & Johnson more than a drugmaker?: Business description; Revenue by segment
  • FAQ: Which Johnson & Johnson business contributes more revenue?: Revenue by segment; Business description
  • FAQ: How does MedTech change Johnson & Johnson’s business mix?: Business description; Revenue by segment
  • FAQ: What would Firefly Bio add to Johnson & Johnson?: Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold JNJ

Funds in our ETF coverage that list JNJ among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Evolved U.S. Innovative Healthcare ETF (IEIH)10.24%
PBPH ETF9.35%
VHT ETF8.22%
ProShares - Ultra Health Care (RXL)7.33%
IXJ ETF7.22%
Brookstone Value Stock ETF (BAMV)4.64%
iShares MSCI USA Momentum Factor ETF (MTUM)4.53%
Simplify Health Care ETF (PINK)4.48%
GVLE ETF3.67%
Nuveen Sustainable Core (NSCR)3.63%